D. Boral Capital Maintains Buy on AVITA Medical, Lowers Price Target to $10
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and lowers the price target from $14 to $10.
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and lowers the price target from $14 to $10.